Progress in genetics and the sequencing of the human genome are paving a path toward a new medicine. In their laboratories, researchers are developing new ways to treat and cure disease. Such fields as gene therapy, cell therapy, medicinal biotech and personalized medicine show great promise for treating patients.
Soon, genome analysis will be a regular part of our lives, used to characterize pathologies, personalize treatments or predict the risk of developing a disease. Biotherapies will soon cure diseases that are incurable today.
- Tomorrow’s medicine will be genetic, molecular and cellular
Not only genetic diseases but also complex diseases such as cancer, cardiovascular disease, chronic diseases, etc., will benefit from progress in genomics and biotherapies.
- A personalized and predictive medicine is emerging
It will be capable of adapting disease treatments to our personal genetic profile and identifying the most efficacious medications free of dangerous side effects. This new medicine will also be able to determine disease predisposition.
As a biocluster specialized in genetics and biotech, Genopole is an active participant in the naissance of this unprecedented “genobiomedicine”.
- Promises and first successes of genobiomedicine at Genopole
- Understanding genetics and sequencing
- Understanding stem cells and regenerative medicine
- Understanding gene therapy
Research on the biocluster
In 2017, Illumina, a global leader in genomics, opened its first commercial ad customer center for Europe in Evry, Genopole. The training center will offer demonstrations, instruction, and education in the latest genomics technologies from Illumina for up to 1,000 scientists a year, providing direct links to Illumina’s global network of facilities and in-house experts.
The private laboratory IntegraGen, a specialist in genomics and molecular diagnostics, is partnering with Europe’s leading cancer center Gustave Roussy to deploy an unprecedented high-throughput sequencing platform for oncology. The tool will provide exhaustive analysis of genetic variations and their expression in tumors.
Patients being treated at Gustave Roussy and participating in personalized medicine studies will have their tumors genetically profiled and the results will serve as a basis for therapeutic personalization.
Genethon and the Inserm, in collaboration with teams at the University of Washington and Harvard Medical School in the United States, achieved a new step towards the treatment of myotubular myopathy by gene therapy. The researchers demonstrated the efficacy of administration of a therapeutic vector by a single intravenous injection and identified the dose that restores long-term muscular strength in a large animal model of the disease..
I-Stem, a laboratory specialized in stem cell research, has preclinical studies underway to test the efficacy of cell therapy in retinitis pigmentosa, sickle cell anemia-associated skin ulcers, and Huntington’s disease. The first human clinical studies are scheduled for 2015.
Phase one clinical trials were launched for the first of a new class of medications targeting cancers that are resistant to conventional therapies. The drug, called Dbait, was developed by the Genopole company DNA Therapeutics in conjunction with Curie-Cancer (in charge of industrial research partnerships for the Institut Curie).
The initial results for this new and promising targeted medication demonstrated its efficacy and good tolerance in chemotherapy-resistant metastatic melanoma.
More details : A characteristic of resistant cancers is that they are good at repairing DNA damaged by cancer treatments such as radiotherapy or chemotherapy. Dbait is a “Signal interfering DNA” that acts as a decoy to disrupt this post-treatment DNA repair capacity, and thus augment the efficacy of the curative treatment.